Santen Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Santen Pharmaceutical has a total shareholder equity of ¥288.3B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥409.1B and ¥120.8B respectively. Santen Pharmaceutical's EBIT is ¥51.0B making its interest coverage ratio 333.1. It has cash and short-term investments of ¥84.4B.
Key information
0%
Debt to equity ratio
JP¥0
Debt
| Interest coverage ratio | 333.1x |
| Cash | JP¥84.44b |
| Equity | JP¥288.25b |
| Total liabilities | JP¥120.83b |
| Total assets | JP¥409.09b |
Recent financial health updates
No updates
Recent updates
Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Nov 18
Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk
Oct 14Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)
Aug 31Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares
Jun 25Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?
May 08Financial Position Analysis
Short Term Liabilities: 4536's short term assets (¥218.5B) exceed its short term liabilities (¥83.9B).
Long Term Liabilities: 4536's short term assets (¥218.5B) exceed its long term liabilities (¥37.0B).
Debt to Equity History and Analysis
Debt Level: 4536 is debt free.
Reducing Debt: 4536 had no debt 5 years ago.
Debt Coverage: 4536 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 4536 has no debt, therefore coverage of interest payments is not a concern.